Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics for $1.5 billion (1.4 billion euros)—but Roche shares dipped over a disappointing study on a key lung cancer treatment.
This article was originally published on this website.
